SABS Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
23.4M
+16.9%
20.0M
+26.8%
15.8M
+24.4%
12.7M
+30.3%
9.7M
R&D
16.2M
+20.7%
13.4M
+24.9%
10.7M
+19.6%
9.0M
+28.2%
7.0M
SG&A
7.2M
+9.2%
6.6M
+30.9%
5.0M
+35.9%
3.7M
+35.6%
2.7M
Operating Income
-23377000
-16.9%
-19997736
-26.8%
-15770231
-24.4%
-12678969
-30.3%
-9732000
EBITDA
-22563965
-17.1%
-19266771
-28.4%
-15006932
-26.4%
-11870088
-32.2%
-8979595
Net Income
-22491000
-19.2%
-18868885
-11.9%
-16860743
-137.1%
45.4M
+549.3%
-10114000
EPS (Basic)
$-0.28
+20.0%
$-0.35
-483.3%
$-0.06
-112.0%
$0.50
+145.9%
$-1.09
EPS (Diluted)
$-0.28
+20.0%
$-0.35
-1650.0%
$-0.02
+90.5%
$-0.21
+80.7%
$-1.09
Shares (Diluted)
79.8M
+48.9%
53.6M
-64.0%
148.9M
+91.2%
77.9M
+737.7%
9.3M
SAB Biotherapeutics (SABS) โ€” Financials